Made in Colombia

News Releases

Nicolás Echavarría Mesa Joins PharmaCielo Colombia Board of Directors

RIONEGRO, Colombia (July 15, 2016) — PharmaCielo Colombia Holdings S.A.S., the Colombian subsidiary of PharmaCielo Ltd., is pleased to announce the appointment of Nicolás Echavarría Mesa to its Board of Directors. Formerly the Head of Mission of Colombia to the European Union in Brussels and Ambassador of Colombia to Belgium and Luxembourg, Mr. Echavarría is a seasoned expert in export, logistics and marketing, having devoted his career to promoting Colombian agricultural products to the world.

“Mr. Echavarría brings to our Colombian Board of Directors unparalleled experience marketing Colombian agricultural goods to world markets,” said PharmaCielo Colombia Holdings Chairman Major General Jose Vicente Urueña Molina. “We look forward to his international business and trade insights and contributions as we develop the operation and global markets.”

Currently, Mr. Echavarría is general manager of C.I. Banafrut S.A., an international marketer of bananas and plantains, and was previously general manager of Trópica Ltda. and Zúñiga Bananeras, commercial manager of C.I. Uniban S.A. and manager of Roldán y Cía Ltda., a cargo management logistics company.

Mr. Echavarría brings significant board of director experience to the company. He has served on the boards of numerous companies including Isagen, Corpouraba, Agrícola Montecristo S.A., Agrícola Bahíagrande S.A., Simesa S.A. and C.I. Valley Farms as well as the City of Medellin, Metroplus, the Museum of Antioquia and Augura, the association of Colombian banana producers.

Mr. Echavarría holds an MSc in Development Economics from the University of Sussex in England, where his thesis focused on the promotion of Colombian exports. As an undergraduate, he studied at Paris-Sorbonne University, then earned a BA in Economics with honours from McGill University in Montréal, Canada. He is a native of Medellin, Colombia.

This announcement comes shortly after the company was officially granted a manufacturing licence from the Ministry of Health and Social Protection to process cannabis plants for medical and scientific purposes. This allows PharmaCielo to apply for a licence to grow cannabis plants and brings the company one step closer to becoming a fully integrated licensed grower and manufacturer of cannabis oil extracts.

About PharmaCielo Colombia Holdings S.A.S.

PharmaCielo Colombia Holdings S.A.S. is a wholly owned subsidiary of PharmaCielo Ltd., a global company privately held and headquartered in Canada with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors of standardized medical cannabis products. 

The boards of directors and executive teams of PharmaCielo Ltd. and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with the relevant expertise to ensure long-term success. The team recognized the significant role Colombia’s ideal location would play in building a sustainable business in the medical cannabis industry and has built a strong business plan focused on supplying the international medical marketplace.

PharmaCielo Colombia Holdings S.A.S. is headquartered at the company’s Nursery and Propagation Centre based in Rionegro, Colombia.

 

This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.